Market Currents
GSK and J&J (JNJ) start Phase III trials of sirukumab for treating moderate-to-severe...
-
Thursday, August 23, 2012, 9:35 AM ETGSK and J&J (JNJ) start Phase III trials of sirukumab for treating moderate-to-severe rheumatoid arthritis. Sirukumab is among a number of drugs under development for the multi-billion dollar market for treating RA, which affects 1.5M Americans and 23.5M people globally. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
